ANALYSIS OF SERUM OCTASE CONCENTRATIONS IN PATIENTS WITH PROSTATE CANCER
https://doi.org/10.17650/1726-9776-2009-5-3-52-56
Abstract
Objective: to estimate the diagnostic value of octase in patients with prostate cancer (PC) to detect whether they have metastases to the skeleton.
Subjects and methods. To examine the impact of PC on the serum level of octase, the study included 58 PC patients who had received various treatment modalities and 8 control males without PC.
Results. Higher serum octase concentrations in PC patients receiving the maximum androgenic blockade allow one to suspect metastatic progression of a tumor to the skeleton, which necessitates osteoscintigraphy in these patients.
Discussion. The findings lead to the conclusion that octase may be used in the screening of PC patients receiving antiandrogen therapy in order to predict whether there will be bone metastases.
About the Authors
M. E. Grigoryev
Department of Urology, Russian State University Medical University, Russian Agency for Health Care
Russian Federation
Russian Federation
V. B. Matveyev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
V. A. Konorev
Department of Urology, Russian State University Medical University, Russian Agency for Health Care
Russian Federation
Russian Federation
A. A. Aksenov
Department of Oncology, Russian State Medical University, Russian Agency for Health Care, Moscow
Russian Federation
Russian Federation
A. D. Ryzhkov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15—36.
2. Бухаркин Б.В. Современные методы лечения местнораспространенного и диссеминированного рака предстательной железы. Дис. … докт. мед. наук. М., 1995.
3. Клиническая онкоурология. Под ред. Б.П. Матвеева. М.: Вердана, 2003. с. 547—87.
4. Fowler J.E., Bigler S.A., White P.C., Duncan W.L. Hormone therapy for locally advanced prostate cancer. J Urol 2002;168:546—9.
5. Bruder J.M., Welch M.D. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen deprivation [abstract]. J Bone Miner Res 2002;17:411.
6. Coates P.S., Wagner J., Ribich J., Trump D.L., Nelson J.B., Greenspan S.L. Acute androgen deprivation causes early rapid bone loss: a longitudinal study [abstract]. J Bone Miner Res 2002;17:155.
7. Mittan D., Lee S., Miller E. et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656—61.
8. Preston D.M., Torrens J.I., Harding P. et al. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002;5:304—10.
9. Hatano T., Oishi Y., Furuta A. et al. Incidence of bone fracture in patients receiving luteinising hormone-releasing hormone agonists for prostate cancer. BJU Int 2000;86:449—52.
10. Modi S., Wood L., Siminoski K. et al. A comparison of prevalence of osteoporosis and vertebral fractures in men with prostate cancer on various androgen deprivation therapies: preliminary report [abstract]. Proc Am Soc Clin Oncol 2001;20(Suppl B):167.
11. Melton L.J., Alothman K.I., Khosla S. et al. Fracture risk following bilateral orhiectomy. J Urol 2003;169:1747—50.
12. Oefelein M., Ricchuitti V., Conrad W. et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001;166:1724—8.
13. Sundkvist G.M., Algren L., Lilja B., Mattson S. Quantitative bone scintigraphy in prostatic carcinoma — long-term response to treatment. Nuklearmedizin 1993;32(5):231—5.
14. Koizumi M. Вone scintigraphy in oncology. Tokyo: Mediculture, 2000.
15. Насонов Е.Л., Скрипникова И.А., Насонова В.А. Проблемы остеопороза в ревматологии. М., 1997.
16. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2(8):563—72.
17. Bettica P., Moro L. Biochemical markers of bone metabolism in the assessment osteoporosis. JIFCC 1995;7(1):16—22.
18. Withold W., Degenhardt S., Castelli D. et al. Monitoring of osteoblast activity with an immunoradiometric assay for determination of bone alkaline phosphatase mass concentration in patients receiving renal transplantats. Clinica Chimica Acta 1994;225:137—46.
Review
For citations:
Grigoryev M.E., Matveyev V.B., Konorev V.A., Aksenov A.A., Ryzhkov A.D. ANALYSIS OF SERUM OCTASE CONCENTRATIONS IN PATIENTS WITH PROSTATE CANCER. Cancer Urology. 2009;5(3):52-56. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-3-52-56
Views:
773
Email this article 